Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer
| Autor: | Zhan-Xiong Xue, Zhenzhai Cai, Su Xiaoping, Yue-Sheng Zhu, Weihong Sun, Jing Zhang, Le-Yi Ni, Hejie Yu, Yangyang Teng, Limiao Lin, Xiangyang Xue, Haiping Song, Yaojun Yu, Xian Shen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Colorectal cancer
T-Lymphocytes medicine.medical_treatment 030231 tropical medicine Immunology Mice 03 medical and health sciences Lymphocytes Tumor-Infiltrating 0302 clinical medicine Cancer immunotherapy Antigens Neoplasm HLA Antigens Animals Humans Immunology and Allergy Medicine In patient 030212 general & internal medicine Homeodomain Proteins Pharmacology Antitumor activity integumentary system business.industry Histocompatibility Antigens Class II Immunotherapy medicine.disease Sphingomyelin Phosphodiesterase Cancer research Cancer vaccine Colorectal Neoplasms Peptides business Peptide Hydrolases |
| Zdroj: | Human Vaccines & Immunotherapeutics. 18:1-11 |
| ISSN: | 2164-554X 2164-5515 |
| DOI: | 10.1080/21645515.2021.1891814 |
| Popis: | Neoantigens play a crucial role in cancer immunotherapy. However, the effectiveness and safety of neoantigen-based immunotherapies in patients with colorectal cancer (CRC), particularly in the Chinese population, have not been well studied. This study explored the feasibility and effectiveness of neoantigens in the treatment of CRC. Whole-exome sequencing (WES) and transcriptome sequencing were used to identify somatic mutations, RNA expression, and human leukocyte antigen (HLA) alleles. Neoantigen candidates were predicted, and immunogenicity was assessed. The neoantigens TSHZ3-L523P, RARA-R83H, TP53-R248W, EYA2-V333I, and NRAS-G12D from Patient 4 (PW4); TASP1-P161L, RAP1GAP-S215R, MOSPD1-V63I, and NAV2-D1973N from Patient 10 (PW10); and HAVCR2-F39V, SEC11A-R11L, SMPDL3B-T452M, LRFN3-R118Q, and ULK1-S248L from Patient 11 (HLA-A0201 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|